Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'NSC-100880' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 133 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Strel'tsov, SA; Mikheikin, AL; Nechipurenko, YD
      Interaction of topotecan, DNA tapoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 2. Formation of topotecan-DNA complex containing several DNA molecules

      MOLECULAR BIOLOGY
    2. Gamucci, T; Paridaens, R; Heinrich, B; Schellens, JH; Pavlidis, N; Verweij, J; Sessa, C; Kaye, S; Roelvink, M; Wanders, J; Hanauske, A
      Activity and toxicity of GI147211 in breast, colorectal and non-small-celllung cancer patients: An EORTC-ECSG phase II clinical study

      ANNALS OF ONCOLOGY
    3. Sorensen, M; Jensen, PB; Herrstedt, J; Hirsch, FR; Hansen, HH
      A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer

      ANNALS OF ONCOLOGY
    4. Yanase, K; Sugimoto, Y; Tsukahara, S; Oh-hara, T; Andoh, T; Tsuruo, T
      Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma

      JAPANESE JOURNAL OF CANCER RESEARCH
    5. Komaki, R; Janjan, NA; Ajani, JA; Lynch, PM; Fairweather, JS; Raijman, I; Blumenshein, GR; Ho, L; Pisters, PWT; Feig, BW; Walsh, GL; Pazdur, R
      Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors

      ONCOLOGY-NEW YORK
    6. Boige, V; Raymond, E; Faivre, S; Gatineau, M; Meely, K; Mekhaldi, S; Pautier, P; Ducreux, M; Rixe, O; Armand, JP
      Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer

      JOURNAL OF CLINICAL ONCOLOGY
    7. Platzer, P; Thalhammer, T; Hamilton, G; Ulsperger, E; Rosenberg, E; Wissiack, R; Jager, W
      Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    8. Vladu, B; Woynarowski, JM; Manikumar, G; Wani, MC; Wall, ME; Von Hoff, DD; Wadkins, RM
      7-and 10-substituted camptothecins: Dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7-and 10-substituents

      MOLECULAR PHARMACOLOGY
    9. Frangoul, H; Ames, MM; Mosher, RB; Reid, JM; Krailo, MD; Seibel, NL; Shaw, DWW; Steinherz, PG; Whitlock, JA; Holcenberg, JS
      Phase I study of topotecan administered as a 21-day continuous infusion inchildren with recurrent solid tumors: A report from the Children's Cancer Group

      CLINICAL CANCER RESEARCH
    10. Subrahmanyam, D; Sarma, VM; Venkateswarlu, A; Sastry, TVRS; Kulakarni, AP; Rao, DS; Reddy, KVSRK
      In vitro cytotoxicity of 5-aminosubstituted 20(S)-camptothecins. Part 1

      BIOORGANIC & MEDICINAL CHEMISTRY
    11. Subrahmanyam, D; Venkateswarlu, A; Rao, KV; Sastry, TVRS; Vandana, G; Kumar, SA
      Novel C-ring analogues of 20(S)-camptothecin-Part-2: Synthesis and in vitro cytotoxicity of 5-C-substituted 20(S)-camptothecin analogues

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    12. Lawrence, RA; Izbicka, E; De Jager, RL; Tohgo, A; Clark, GM; Weitman, SD; Rowinsky, EK; Von Hoff, DD
      Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells

      ANTI-CANCER DRUGS
    13. Tsunoda, T; Tanimura, H; Hotta, T; Tani, M; Iwahashi, M; Tanaka, H; Matsuda, K; Yamaue, H
      In vitro antitumor effect of topoisomerase-I inhibitor, CPT-11, on freshlyisolated human gastric and colorectal cancer

      ANTICANCER RESEARCH
    14. Kollmannsberger, C; Mross, K; Jakob, A; Kanz, L; Bokemeyer, C
      Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience

      ONCOLOGY
    15. Ormrod, D; Spencer, CM
      Topotecan - A review of its efficacy in small cell lung cancer

      DRUGS
    16. de Jonge, MJA; Verweij, J; Loos, WJ; Dallaire, BK; Sparreboom, A
      Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    17. ECKHARDT SG; BAKER SD; ECKARDT JR; BURKE TG; WARNER DL; KUHN JG; RODRIGUEZ G; FIELDS S; THURMAN A; SMITH L; ROTHENBERG ML; WHITE L; WISSEL P; KUNKA R; DEPEE S; LITTLEFIELD D; BURRIS HA; VONHOFF DD; ROWINSKY EK
      PHASE-I AND PHARMACOKINETIC STUDY OF GI147211, A WATER-SOLUBLE CAMPTOTHECIN ANALOG, ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS

      Clinical cancer research
    18. ECKHARDT SG; BAKER SD; ECKARDT JR; BURKE TG; WARNER DL; KUHN JG; RODRIGUEZ G; FIELDS S; THURMAN A; SMITH L; ROTHENBERG ML; WHITE L; WISSEL P; KUNKA R; DEPEE S; LITTLEFIELD D; BURRIS HA; VONHOFF DD; ROWINSKY EK
      PHASE-I AND PHARMACOKINETIC STUDY OF GI147211, A WATER-SOLUBLE CAMPTOTHECIN ANALOG, ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS

      Clinical cancer research
    19. EDER JP; SUPKO JG; LYNCH T; BRYANT M; VOSBURGH E; SHULMAN LN; XU GX; KUFE DW
      PHASE-I TRIAL OF THE COLLOIDAL DISPERSION FORMULATION OF 9-AMINO-20(S)-CAMPTOTHECIN ADMINISTERED AS A 72-HOUR CONTINUOUS INTRAVENOUS-INFUSION

      Clinical cancer research
    20. EDER JP; SUPKO JG; LYNCH T; BRYANT M; VOSBURGH E; SHULMAN LN; XU GX; KUFE DW
      PHASE-I TRIAL OF THE COLLOIDAL DISPERSION FORMULATION OF 9-AMINO-20(S)-CAMPTOTHECIN ADMINISTERED AS A 72-HOUR CONTINUOUS INTRAVENOUS-INFUSION

      Clinical cancer research
    21. SHIMIZU Y; NAGATA H; KIKUCHI Y; UEMZAWA S; HASUMI K; YOKOKURA T
      CYTOTOXIC AGENTS ACTIVE AGAINST MUCINOUS ADENOCARCINOMA OF THE OVARY

      Oncology Reports
    22. LIN XR; WILKINSON DI; FARBER EM
      CAMPTOTHECIN INDUCES DIFFERENTIATION, TISSUE TRANSGLUTAMINASE AND APOPTOSIS IN CULTURED KERATINOCYTES

      Experimental dermatology
    23. MINDERMAN H; CAO SS; RUSTUM YM
      RATIONAL DESIGN OF IRINOTECAN ADMINISTRATION BASED ON PRECLINICAL MODELS

      Oncology
    24. PITOT HC
      US PIVOTAL STUDIES OF IRINOTECAN IN COLORECTAL-CARCINOMA

      Oncology
    25. SALTZ LB
      IRINOTECAN IN THE FIRST-LINE TREATMENT OF COLORECTAL-CANCER

      Oncology
    26. KANO Y; AKUTSU M; TSUNODA S; MORI K; SUZUKI K; ADACHI KI
      IN-VITRO SCHEDULE-DEPENDENT INTERACTION BETWEEN PACLITAXEL AND SN-38 (THE ACTIVE METABOLITE OF IRINOTECAN) IN HUMAN CARCINOMA CELL-LINES

      Cancer chemotherapy and pharmacology
    27. CHOURPA I; MILLOT JM; SOCKALINGUM GD; RIOU JF; MANFAIT M
      KINETICS OF LACTONE HYDROLYSIS IN ANTITUMOR DRUGS OF CAMPTOTHECIN SERIES AS STUDIED BY FLUORESCENCE SPECTROSCOPY

      Biochimica et biophysica acta (G). General subjects
    28. LEE JH; LEE JM; KIM JK; AHN SK; LEE SJ; KIM MY; JEW SS; PARK JG; HONG CI
      ANTITUMOR-ACTIVITY OF 7-[2-(N-ISOPROPYLAMINO)ETHYL]-(20S)-CAMPTOTHECIN, CKD602, AS A POTENT DNA TOPOISOMERASE-I INHIBITOR

      Archives of pharmacal research
    29. PLATZER P; SCHADEN S; THALHAMMER T; HAMILTON G; ROSENBERG B; SILGONER I; JAGER W
      BIOTRANSFORMATION OF TOPOTECAN IN THE ISOLATED-PERFUSED RAT-LIVER - IDENTIFICATION OF 3 NOVEL METABOLITES

      Anticancer research
    30. PLATZER P; HERZOG W; THALHAMMER T; HAMILTON G; HABERL I; JAGER W
      FORMATION OF A NOVEL TOPOTECAN METABOLITE IN THE HORMONE-INDEPENDENT HUMAN PROSTATE CARCINOMA CELL-LINES DU-145 AND PC-3

      Anticancer research
    31. WALL ME
      CAMPTOTHECIN AND TAXOL - DISCOVERY TO CLINIC

      Medicinal research reviews
    32. Pazdur, R; Medgyesy, DC; Winn, RJ; Dakhil, SR; Moore, DF; Scalzo, A; Hoff, PM; Arbuck, SG; Abbruzzese, JL
      Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma

      INVESTIGATIONAL NEW DRUGS
    33. SIU LL; ROWINSKY EK
      A RISK-BENEFIT ASSESSMENT OF IRINOTECAN IN SOLID TUMORS

      Drug safety
    34. CAO ZS; HARRIS N; KOZIELSKI A; VARDEMAN D; STEHLIN JS; GIOVANELLA B
      ALKYL ESTERS OF CAMPTOTHECIN AND 9-NITROCAMPTOTHECIN - SYNTHESIS, IN-VITRO PHARMACOKINETICS, TOXICITY, AND ANTITUMOR-ACTIVITY

      Journal of medicinal chemistry
    35. IRVIN WP; PRICE FV; BAILEY H; GELDER M; ROSENBLUTH R; DURIVAGE HJ; POTKUL RK
      A PHASE-II STUDY OF IRINOTECAN (CPT-11) IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE CERVIX

      Cancer
    36. PAZARES L; KUNKA R; DEMARIA D; CASSIDY J; ALDEN M; BERANEK P; KAYE S; LITTLEFIELD D; REILLY D; DEPEE S; WISSEL P; TWELVES C; ODWYER P
      A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE NEW TOPOISOMERASEINHIBITOR GI147211 GIVEN AS A 72-H CONTINUOUS-INFUSION

      British Journal of Cancer
    37. GUICHARD S; HENNEBELLE I; BUGAT R; CANAL P
      CELLULAR INTERACTIONS OF 5-FLUOROURACIL AND THE CAMPTOTHECIN ANALOG CPT-11 (IRINOTECAN) IN A HUMAN COLORECTAL-CARCINOMA CELL-LINE

      Biochemical pharmacology
    38. WARNER DL; BURKE TG
      SIMPLE AND VERSATILE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS QUANTITATION OF THE LACTONE AND CARBOXYLATE FORMS OF CAMPTOTHECIN ANTICANCER DRUGS

      Journal of chromatography B. Biomedical sciences and applications
    39. THOMPSON J; ZAMBONI WC; CHESHIRE PJ; LUTZ L; LUO XL; LI YL; HOUGHTON JA; STEWART CF; HOUGHTON PJ
      EFFICACY OF SYSTEMIC ADMINISTRATION OF IRINOTECAN AGAINST NEUROBLASTOMA XENOGRAFTS

      Clinical cancer research
    40. ZHANG RW; CAI QY; LINDSEY JR; LI YF; CHAMBLESS B; NAGUIB FNM
      ANTITUMOR-ACTIVITY AND PHARMACOKINETICS FOLLOWING ORAL-ADMINISTRATIONOF NATURAL PRODUCT DNA TOPOISOMERASE-I INHIBITORS 10-HYDROXYCAMPTOTHECIN AND CAMPTOTHECIN IN SCID MICE BEARING HUMAN BREAST-CANCER XENOGRAFTS

      International journal of oncology
    41. PITOT HC; WENDER DB; OCONNELL MJ; SCHROEDER G; GOLDBERG RM; RUBIN J; MAILLIARD JA; KNOST JA; GHOSH C; KIRSCHLING RJ; LEVITT R; WINDSCHITL HE
      PHASE-II TRIAL OF IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA

      Journal of clinical oncology
    42. VERSCHRAEGEN CF; LEVY T; KUDELKA AP; LLERENA E; ENDE K; FREEDMAN RS; EDWARDS CL; HORD M; STEGER M; KAPLAN AL; KIEBACK D; FISHMAN A; KAVANAGH JJ
      PHASE-II STUDY OF IRINOTECAN IN PRIOR CHEMOTHERAPY-TREATED SQUAMOUS-CELL CARCINOMA OF THE CERVIX

      Journal of clinical oncology
    43. JONES CB; CLEMENTS MK; WASI S; DAOUD SS
      SENSITIVITY TO CAMPTOTHECIN OF HUMAN BREAST-CARCINOMA AND NORMAL ENDOTHELIAL-CELLS

      Cancer chemotherapy and pharmacology
    44. NAKATSU S; KONDO S; KONDO Y; YIN DL; PETERSON JW; KAAKAJI R; MORIMURA T; KIKUCHI H; TAKEUCHI J; BARNETT GH
      INDUCTION OF APOPTOSIS IN MULTIDRUG-RESISTANT (MDR) HUMAN GLIOBLASTOMA CELLS BY SN-38, A METABOLITE OF THE CAMPTOTHECIN DERIVATIVE CPT-11

      Cancer chemotherapy and pharmacology
    45. SALTZ LB; SCHWARTZ GK; ILSON DH; QUAN V; KELSEN DP
      A PHASE-II STUDY OF TOPOTECAN ADMINISTERED 5 TIMES DAILY IN PATIENTS WITH ADVANCED GASTRIC-CANCER

      American journal of clinical oncology
    46. RAMANATHAN RK; BELANI CP
      CHEMOTHERAPY FOR ADVANCED NONSMALL CELL LUNG-CANCER - PAST, PRESENT, AND FUTURE

      Seminars in oncology
    47. DENNIS MJ; BEIJNEN JH; GROCHOW LB; VANWARMERDAM LJC
      AN OVERVIEW OF THE CLINICAL-PHARMACOLOGY OF TOPOTECAN

      Seminars in oncology
    48. CAO ZS
      AN ALTERNATIVE PREPARATION OF CAMPTOTHECIN 20(S)-ACETATE

      Synthetic communications
    49. ZHAO RL; ALSAID NH; STERNBACH DL; LOWN JW
      CAMPTOTHECIN AND MINOR-GROOVE BINDER HYBRID MOLECULES - SYNTHESIS, INHIBITION OF TOPOISOMERASE-I, AND ANTICANCER CYTOTOXICITY IN-VITRO

      Journal of medicinal chemistry
    50. DEY J; WARNER IM
      SPECTROSCOPIC AND PHOTOPHYSICAL STUDIES OF THE ANTICANCER DRUG - CAMPTOTHECIN

      Journal of luminescence
    51. GERRITS CJH; SCHELLENS JHM; CREEMERS GJ; WISSEL P; PLANTING AST; PRITCHARD JF; DEPEE S; DEBOERDENNERT M; HARTEVELD M; VERWEIJ J
      THE BIOAVAILABILITY OF ORAL GI147211 (GG211), A NEW TOPOISOMERASE-I INHIBITOR

      British Journal of Cancer
    52. GERRITS CJH; DEJONGE MJA; SCHELLENS JHM; STOTER G; VERWEIJ J
      TOPOISOMERASE-I INHIBITORS - THE RELEVANCE OF PROLONGED EXPOSURE FOR PRESENT CLINICAL DEVELOPMENT

      British Journal of Cancer
    53. VASEY PA; KAYE SB
      COMBINED INHIBITION OF TOPOISOMERASE-I AND TOPOISOMERASE-II - IS THISA WORTHWHILE FEASIBLE STRATEGY/

      British Journal of Cancer
    54. SHIBATA Y; TAKIGUCHI H; TAMURA K; YAMANAKA K; TEZUKA M; ABIKO Y
      STIMULATION OF INTERLEUKIN-1 BETA-CONVERTING ENZYME-ACTIVITY DURING GROWTH-INHIBITION BY CPT-11 IN THE HUMAN MYELOID-LEUKEMIA CELL-LINE K562

      Biochemical and molecular medicine
    55. KAMII Y; TSUCHIDA Y; YOKOMORI K
      EFFECTS OF CPT-11 ON A HUMAN RHABDOMYOSARCOMA IN NUDE-MICE AND IN CULTURE

      International journal of pediatric hematology/oncology
    56. MASUDA N; KUDOH S; FUKUOKA M
      IRINOTECAN (CPT-11) - PHARMACOLOGY AND CLINICAL-APPLICATIONS

      Critical reviews in oncology/hematology
    57. DEY J; WARNER IM
      EXCITED-STATE TAUTOMERIZATION OF CAMPTOTHECIN IN AQUEOUS-SOLUTION

      Journal of photochemistry and photobiology. A, Chemistry
    58. CLEMENTS MK; WASI S; DAOUD SS
      CAMPTOTHECIN EXHIBITS SELECTIVE CYTOTOXICITY TOWARDS HUMAN BREAST-CARCINOMA AS COMPARED TO NORMAL BOVINE ENDOTHELIAL-CELLS IN-VITRO

      Anti-cancer drugs
    59. ROWINSKY EK; GROCHOW LB; SARTORIUS SE; BOWLING MK; KAUFMANN SH; PEEREBOOM D; DONEHOWER RC
      PHASE-I AND PHARMACOLOGICAL STUDY OF HIGH-DOSES OF THE TOPOISOMERASE-I INHIBITOR TOPOTECAN WITH GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH SOLID TUMORS

      Journal of clinical oncology
    60. DAHUT W; HAROLD N; TAKIMOTO C; ALLEGRA C; CHEN A; HAMILTON JM; ARBUCK S; SORENSEN M; GROLLMAN F; NAKASHIMA H; LIEBERMAN R; LIANG M; CORSE W; GREM J
      PHASE-I AND PHARMACOLOGICAL STUDY OF 9-AMINOCAMPTOTHECIN GIVEN BY 72-HOUR INFUSION IN ADULT CANCER-PATIENTS

      Journal of clinical oncology
    61. SALTZ LB; KANOWITZ J; KEMENY NE; SCHAAF L; SPRIGGS D; STATON BA; BERKERY R; STEGER C; ENG M; DIETZ A; LOCKER P; KELSEN DP
      PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF IRINOTECAN, FLUOROURACIL, ANTI LEUCOVORIN IN PATIENTS WITH ADVANCED SOLID TUMORS

      Journal of clinical oncology
    62. LIEVANO G; MIROCHNIK Y; RUBENSTEIN M; SHAW M; GUINAN P
      ANTITUMOR EFFECT OF CPT-11, A NEW DERIVATIVE OF CAMPTOTHECIN, AGAINSTHUMAN PROSTATE-CANCER (PC-3) IN-VITRO AND PROSTATE RAT-TUMOR (AT-3) IN-VIVO

      Methods and findings in experimental and clinical pharmacology
    63. WALL ME; WANI MC
      CAMPTOTHECIN AND TAXOL - FROM DISCOVERY TO CLINIC

      Journal of ethnopharmacology
    64. HINZ HR; HARRIS NJ; GIOVANELLA BC; EZELL EL; LIEHR JG
      STABILITIES OF H-3-LABELED AND H-2-LABELED CAMPTOTHECINS

      Journal of labelled compounds & radiopharmaceuticals
    65. LAMOND JP; WANG MZ; KINSELLA TJ; BOOTHMAN DA
      CONCENTRATION AND TIMING DEPENDENCE OF LETHALITY ENHANCEMENT BETWEEN TOPOTECAN, A TOPOISOMERASE-I INHIBITOR, AND IONIZING-RADIATION

      International journal of radiation oncology, biology, physics
    66. AHMED AE; JACOB S; GIOVANELLA BC; KOZIELSKI AJ; STEHLIN JS; LIEHR JG
      INFLUENCE OF ROUTE OF ADMINISTRATION ON [H-3] CAMPTOTHECIN DISTRIBUTION AND TUMOR UPTAKE IN CASE BEARING NUDE-MICE - WHOLE-BODY AUTORADIOGRAGHIC STUDIES

      Cancer chemotherapy and pharmacology
    67. VANWARMERDAM LJC; CREEMERS GJ; RODENHUIS S; ROSING H; DEBOERDENNERT M; SCHELLENS JHM; HUININK WWT; DAVIES BE; MAES RAA; VERWEIJ J; BEIJNEN JH
      PHARMACOKINETICS AND PHARMACODYNAMICS OF TOPOTECAN GIVEN ON A DAILY-TIMES-5-SCHEDULE IN PHASE-II CLINICAL-TRIALS USING A LIMITED-SAMPLING PROCEDURE

      Cancer chemotherapy and pharmacology
    68. VERWEIJ J
      NEW PROMISING ANTICANCER AGENTS IN DEVELOPMENT - WHAT COMES NEXT

      Cancer chemotherapy and pharmacology
    69. SUGARMAN SM; ZOU YY; WASAN K; POIROT K; KUMI R; REDDY S; PEREZSOLER R
      LIPID COMPLEXED CAMPTOTHECIN - FORMULATION AND INITIAL BIODISTRIBUTION AND ANTITUMOR-ACTIVITY STUDIES

      Cancer chemotherapy and pharmacology
    70. HERBEN VMM; HUININK WWTB; BEIJNEN JH
      CLINICAL PHARMACOKINETICS OF TOPOTECAN

      Clinical pharmacokinetics
    71. CAO ZS
      PREPARATION OF 14-NITROCAMPTOTHECIN DERIVATIVES BY REACTIONS OF CAMPTOTHECIN WITH NITRONIUM TETRAFLUOROBORATE IN ACIDIC SOLVENTS

      Journal of the Chemical Society. Perkin transactions. I
    72. LAMOND JP; MEHTA MP; BOOTHMAN DA
      THE POTENTIAL OF TOPOISOMERASE-I INHIBITORS IN THE TREATMENT OF CNS MALIGNANCIES - REPORT OF A SYNERGISTIC EFFECT BETWEEN TOPOTECAN AND RADIATION

      Journal of neuro-oncology
    73. LACKEY K; STERNBACH DD; CROOM DK; EMERSON DL; EVANS MG; LEITNER PL; LUZZIO MJ; MCINTYRE G; VUONG A; YATES J; BESTERMAN JM
      WATER-SOLUBLE INHIBITORS OF TOPOISOMERASE-I - QUATERNARY SALT DERIVATIVES OF CAMPTOTHECIN

      Journal of medicinal chemistry
    74. COUTEAU C; YAKENDJI K; TERRET C; GONCALVES E; ARMAND JP
      TAXOTER (DOCETAXEL) AND CPT-11 (IRINOTECA N) - THE PHASE-I TRIALS

      Bulletin du cancer
    75. GERRITS CJH; CREEMERS GJ; SCHELLENS JHM; WISSEL P; PLANTING AST; KUNKA R; SELINGER K; DEBOERDENNERT M; MARIJNEN Y; HARTEVELD M; VERWEIJ J
      PHASE-I AND PHARMACOLOGICAL STUDY OF THE NEW TOPOISOMERASE-I INHIBITOR GI147211, USING A DAILY X 5 INTRAVENOUS ADMINISTRATION

      British Journal of Cancer
    76. DAOUD SS; FETOUH MI; GIOVANELLA BC
      ANTITUMOR EFFECT OF LIPOSOME-INCORPORATED CAMPTOTHECIN IN HUMAN-MALIGNANT XENOGRAFTS

      Anti-cancer drugs
    77. VERWEIJ J; SCHELLENS HM
      TOPOISOMERASE-I INHIBITION - A NEW TARGET OR NEW MISSILES

      Annals of oncology
    78. CATIMEL G; CHABOT GG; GUASTALLA JP; DUMORTIER A; COTE C; ENGEL C; GOUYETTE A; MATHIEUBOUE A; MAHJOUBI M; CLAVEL M
      PHASE-I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTEREDDAILY FOR 3 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED SOLID TUMORS

      Annals of oncology
    79. CHABOT GG; ABIGERGES D; CATIMEL G; CULINE S; DEFORNI R; EXTRA JM; MAHJOUBI H; HERAIT P; ARMAND JP; BUGAT R; CLAVEL M; MARTY ME
      POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS

      Annals of oncology
    80. FUJITA Y; YAEGASHI T; SAWADA S; OYAMA H; YOSHIMOTO T; TSURU D
      PARTIAL-PURIFICATION AND CHARACTERIZATION OF AN ESTERASE ACTING ON THE ANTICANCER PRO-DRUGS, 7-ETHYLCAMPTOTHECIN DERIVATIVES

      Biological & pharmaceutical bulletin
    81. MITSUI I; KUMAZAWA E; HIROTA Y; AONUMA M; SUGIMORI M; OHSUKI S; UOTO K; EJIMA A; TERASAWA H; SATO K
      A NEW WATER-SOLUBLE CAMPTOTHECIN DERIVATIVE, DX-8951F, EXHIBITS POTENT ANTITUMOR-ACTIVITY AGAINST HUMAN TUMORS IN-VITRO AND IN-VIVO

      Japanese journal of cancer research
    82. TAKASUNA K; KASAI Y; KITANO Y; MORI K; KOBAYASHI R; HAGIWARA T; KAKIHATA K; HIROHASHI M; NOMURA M; NAGAI E; KAMATAKI T
      PROTECTIVE EFFECTS OF KAMPO MEDICINES AND BAICALIN AGAINST INTESTINALTOXICITY OF A NEW ANTICANCER CAMPTOTHECIN DERIVATIVE, IRINOTECAN HYDROCHLORIDE (CPT-11), IN RATS

      Japanese journal of cancer research
    83. SASAKI Y; HAKUSUI H; MIZUNO S; MORITA M; MIYA T; EGUCHI K; SHINKAI T; TAMURA T; OHE Y; SAIJO N
      A PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF CPT-11 AND ITS ACTIVE METABOLITE SN-38

      Japanese journal of cancer research
    84. SASAKI Y; YOSHIDA Y; SUDOH K; HAKUSUI H; FUJII H; OHTSU T; WAKITA H; IGARASHI T; ITOH K
      PHARMACOLOGICAL CORRELATION BETWEEN TOTAL DRUG CONCENTRATION AND LACTONES OF CPT-11 AND SN-38 IN PATIENTS TREATED WITH CPT-11

      Japanese journal of cancer research
    85. ABIGERGES D; CHABOT GG; ARMAND JP; HERAIT P; GOUYETTE A; GANDIA D
      PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS

      Journal of clinical oncology
    86. HOUGHTON PJ; CHESHIRE PJ; HALLMAN JD; LUTZ L; FRIEDMAN HS; DANKS MK; HOUGHTON JA
      EFFICACY OF TOPOISOMERASE-I INHIBITORS, TOPOTECAN AND IRINOTECAN, ADMINISTERED AT LOW-DOSE LEVELS IN PROTRACTED SCHEDULES TO MICE BEARING XENOGRAFTS OF HUMAN TUMORS

      Cancer chemotherapy and pharmacology
    87. VANWARMERDAM LJC; VERWEIJ J; SCHELLENS JHM; ROSING H; DAVIES BE; DEBOERDENNERT M; MAES RAA; BEIJNEN JH
      PHARMACOKINETICS AND PHARMACODYNAMICS OF TOPOTECAN ADMINISTERED DAILYFOR 5 DAYS EVERY 3 WEEKS

      Cancer chemotherapy and pharmacology
    88. KONDO T; UEDA K; KANO E
      COMBINED EFFECTS OF HYPERTHERMIA AND CPT-11 ON DNA STRAND BREAKS IN MOUSE MAMMARY-CARCINOMA FM3A CELLS

      Anticancer research
    89. OREILLY S; KENNEDY MJ; ROWINSKY EK; DONEHOWER RC
      VINORELBINE AND THE TOPOISOMERASE-1 INHIBITORS - CURRENT AND POTENTIAL ROLES IN BREAST-CANCER CHEMOTHERAPY

      Breast cancer research and treatment
    90. MATSUMOTO Y; FUJIWARA T; NAGAO S
      DETERMINANTS OF DRUG RESPONSE IN CAMPTOTHECIN-11-RESISTANT GLIOMA CELL-LINES

      Journal of neuro-oncology
    91. MASIN JS; BERGER SJ; SETRAKIAN S; STEPNICK DW; BERGER NA
      TOPOISOMERASE-I ACTIVITY IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK

      The Laryngoscope
    92. UEHLING DE; NANTHAKUMAR SS; CROOM D; EMERSON DL; LEITNER PP; LUZZIO MJ; MCINTYRE G; MORTON B; PROFETA S; SISCO J; STERNBACH DD; TONG WQ; VUONG A; BESTERMAN JM
      SYNTHESIS, TOPOISOMERASE-I INHIBITORY ACTIVITY, AND IN-VIVO EVALUATION OF 11-AZACAMPTOTHECIN ANALOGS

      Journal of medicinal chemistry
    93. LUZZIO MJ; BESTERMAN JM; EMERSON DL; EVANS MG; LACKEY K; LEITNER PL; MCINTYRE G; MORTON B; MYERS PL; PEEL M; SISCO JM; STERNBACH DD; TONG WQ; TRUESDALE A; UEHLING DE; VUONG A; YATES J
      SYNTHESIS AND ANTITUMOR-ACTIVITY OF NOVEL WATER-SOLUBLE DERIVATIVES OF CAMPTOTHECIN AS SPECIFIC INHIBITORS OF TOPOISOMERASE-I

      Journal of medicinal chemistry
    94. WEINGART JD; THOMPSON RC; TYLER B; COLVIN OM; BREM H
      LOCAL-DELIVERY OF THE TOPOISOMERASE-I INHIBITOR CAMPTOTHECIN SODIUM PROLONGS SURVIVAL IN THE RAT INTRACRANIAL 9L GLIOSARCOMA MODEL

      International journal of cancer
    95. WALL ME; WANI MC
      CAMPTOTHECIN AND TAXOL - DISCOVERY TO CLINIC - 13TH BRUCE-F-CAIN-MEMORIAL-AWARD-LECTURE

      Cancer research
    96. OBRIEN S; KANTARJIAN H; ELLIS A; ZWELLING L; ESTEY E; KEATING M
      TOPOTECAN IN CHRONIC LYMPHOCYTIC-LEUKEMIA

      Cancer
    97. MI ZH; MALAK H; BURKE TG
      REDUCED ALBUMIN-BINDING PROMOTES THE STABILITY AND ACTIVITY OF TOPOTECAN IN HUMAN BLOOD

      Biochemistry
    98. PARKINSON DR; ARBUCK SG; MOORE T; PLUDA JM; CHRISTIAN MC
      CLINICAL DEVELOPMENT OF ANTICANCER AGENTS FROM NATURAL-PRODUCTS

      Stem cells
    99. BURRIS HA; AWADA A; KUHN JG; ECKARDT JR; COBB PW; RINALDI DA; FIELDS S; SMITH L; VONHOFF DD
      PHASE-I AND PHARMACOKINETIC STUDIES OF TOPOTECAN ADMINISTERED AS A 72OR 120-H CONTINUOUS-INFUSION

      Anti-cancer drugs
    100. SHIMADA Y; ROTHENBERG M; HILSENBECK SG; BURRIS HA; DEGEN D; VONHOFF DD
      ACTIVITY OF CPT-11 (IRINOTECAN HYDROCHLORIDE), A TOPOISOMERASE-I INHIBITOR, AGAINST HUMAN TUMOR COLONY-FORMING-UNITS

      Anti-cancer drugs


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/21 alle ore 05:51:35